Citigroup: The “15th Five-Year Plan” for the development of the pharmaceutical industry favors the first choice for innovative drugs and medical devices, CSPC Group (01093), etc.

The Zhitong Finance App learned that Citibank released a research report saying that the Ministry of Industry and Information Technology and other departments jointly issued the “Fifteenth Five-Year Plan for the Development of the Pharmaceutical Industry”. The core is to push China's pharmaceutical industry from scale-driven growth to innovation-driven and quality-oriented development, and clearly proposed the goal of becoming the world leader by 2030. The plan covers innovative drugs, innovative medical devices, AI-driven drug discovery, and technical fields such as CDMO/CRO, showing that the policy is broadly supporting the entire value chain.

The bank believes that the policy direction favors domestic innovative drugs and biotechnology, AIDD companies, CRO/CDMO service providers, high-end medical devices and in vitro diagnostic (IVD) equipment manufacturers, and innovative traditional Chinese medicine companies. Preferred stocks include Shijiao Group (01093), Hengrui Pharmaceuticals (01276), Cinda Biotech (01801), Collenbotai Biotech (06990), Pharmaceuticals (02269), Tiger Pharmaceuticals (03347), and Insili Intelligence (03696).